Rotavirus vaccines against diarrhoeal disease

Lancet

Volumn 350, Issue 9090, 1997, Pages 1538-1541

  Vesikari, Timo ^a  

^a UNIVERSITY OF TAMPERE MEDICAL SCHOOL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ROTAVIRUS VACCINE; SIMIAN ROTAVIRUS VACCINE;

DIARRHEA; MORTALITY; PRIORITY JOURNAL; SHORT SURVEY; VACCINATION; VIRUS INFECTION;

EID: 0031590611     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(97)03254-6     Document Type: Review

References (42)

1. Bern C, Martines J, de Zoysa I, Glass RI. The magnitude of the global problem of diarrhoeal disease: a ten year update. Bull World Health Organ 1992; 70: 705-14.
2. Trach DD, Clemens JD, Ke NT, et al. Field trial of a locally produced, killed, oral cholera vaccine in Vietnam. Lancet 1997; 349: 231-35.
3. Kotloff KL, Losonsky GA, Nataro JP, et al. Evaluation of the safety, immunogenicity, and efficacy in healthy adults of four doses of live oral hybrid Escherichia coli-Shigella flexneri 2a vaccine strain EcSf2a-2. Vaccine 1995; 13: 495-502.
4. Svennerholm AM, Holmgren J. Oral vaccines against cholera and enterotoxigenic Escherichia coli diarrhoea. Adv Exp Med Biol 1995; 371B: 1623-28.
5. de Zoysa I, Feachem RG. Interventions for the control of diarrhoeal diseases among young children: rotavirus and cholera immunization. Bull World Health Organ 1985; 63: 569-83.
6. Velázquez FR, Matson DO, Calva JJ, et al. Rotavirus infection in infants as protection against subsequent infections. N Engl J Med 1996; 335: 1022-28.
7. Bishop RF, Barnes GL, Cipriani E, Lund JS. Clinical immunity after neonatal rotavirus infection: a prospective longitudinal study in young children. N Engl J Med 1983; 309: 72-76.
8. Bhan MK, Lew JF, Sazawal S, Dak BK, Gentsch JR, Glass RI. Protection conferred by neonatal rotavirus infection against subsequent diarrhoea. J Infect Dis 1993; 168: 282-87.
9. Zissis G, Lambert JP, Marbehant P, et al. Protection studies in colostrum deprived piglets of a bovine rotavirus vaccine candidate using human rotavirus strains for challenge. J Infect Dis 1983; 148: 1061-68.
10. Vesikari T, Isolauri E, Delem A, d'Hondt E, André FE, Zissis G. Immunogenicity and safety of live attenuated bovine rotavirus vaccine strain RIT 4237 in adults and young children. Lancet 1983; 2: 807-11.
11. Vesikari T, Isolauri E, d'Hondt E, Delem A, Zissis G. Protection of infants against rotavirus diarrhoea by RIT 4237 attenuated bovine rotavirus strain vaccine. Lancet 1984; i: 977-81.
12. Vesikari T, Joensuu J. Review of rotavirus vaccine trials in Finland. J Infect Dis 1996; 174 (suppl 1): 81-87.
13. De Mol P, Zissis G, Butzler JP, Mutwewingabo A, André FE. Failure of live, attenuated oral rotavirus vaccine. Lancet 1986; 2: 108.
14. Lanata CF, Black RE, del Aguila R, et al. Protection of Peruvian children against rotavirus diarrhoea of specific serotypes by the RIT 4237 attenuated bovine rotavirus vaccine. J Infect Dis 1989; 159: 452-59.
15. Hanlon P, Hanlon L, Marsh V, et al. A trial of an attenuated bovine rotavirus vaccine (RIT 4237) in Gambian children. Lancet 1987; 1: 1342-45.
16. Clark HF, Borian FE, Bell LM, Modesto K, Gouvea V, Plotkin SA. Protective effect of WC3 vaccine against rotavirus diarrhoea in infants during a predominantly serotype 1 rotavirus season. J Infect Dis 1988; 158: 570-87.
17. Clark HF, Offit PA, Ellis RW, et al. WC3 reassortant vaccines in children. Arch Virol 1996; (suppl) 12: 187-98.
18. Georges-Courbot MC, Monges J, Siopathis MR, et al. Evaluation of the efficacy of a low-passage bovine rotavirus (strain WC3) vaccine in children in Central Africa. Res Virol 1991; 142: 405-11.
19. Kapikian AZ, Flores J, Hoshino Y, et al. Rotavirus: the major etiologic agent of severe infantile diarrhea may be controlled by a 'Jennerian' approach to vaccination. J Infect Dis 1986; 153: 815-22.
20. Vesikari T, Kapikian AZ, Delem A, Zissis G. A comparative trial of rhesus monkey (RRV-1) and bovine (RIT 4237) oral rotavirus vaccines in young children. J Infect Dis 1986; 153: 832-39.
21. Christy C, Madore HP, Pichichero ME, et al. Field trial of rhesus rotavirus vaccines in infants. Pediatr Infect Dis J 1988; 7: 645-50.
22. Rennels MB, Losonsky GA, Young AE, et al. An efficacy trial of rhesus rotavirus vaccine in Maryland. Am J Dis Child 1990; 144: 601-04.
23. Gothefors L, Wadell G, Juto P, et al. Prolonged efficacy of rhesus rotavirus vaccine in Swedish children. J Infect Dis 1989; 159: 753-57.
24. Kapikian AZ, Hoshino Y, Chanock RM, Pérez-Schael I. Efficacy of a quadrivalent rhesus rotavirus-based human rotavirus vaccine aimed at preventing severe rotavirus diarrhoea in infants and young children. J Infect Dis 1996; 174: 65-72.
25. Bernstein DI, Glass RI, Rodgers G, Davidson BL, Sack DA, for the US Rotavirus Vaccine Efficacy Group. Evaluation of rhesus rotavirus monovalent and tetravalent reassortant vaccines in US children. JAMA 1995; 273: 1191-69.
26. Rennels MB, Glass RI, Dennehy PH, et al. Safety and efficacy of high-dose rhesus-human reassortant rotavirus vaccines - report of the National Multicentre Trial. Pediatrics 1996; 97: 7-13.
27. Joensuu J, Koskenniemi E, Pang XL, Vesikari T. A randomized, double-blind, placebo controlled trial of rhesus-human reassortant rotavirus vaccine for prevention of severe rotavirus gastroenteritis. Lancet 1997; (in press).
28. Perez-Schael I, Guntinas MJ, Perez M, et al. Efficacy of the rhesus rotavirus-based quadrivalent vaccine in infants and young children in Venezuela. N Engl J Med 1997; 337: 1181-87.
29. Lanata CF, Midthun K, Black RE, et al. Safety, immunogenicity, and protective efficacy of one and three doses of the tetravalent rhesus rotavirus vaccine in infants in Lima, Peru. J Infect Dis 1996; 174: 268-75.
30. Linhares AC, Gabbay YB, de Freitas RB, et al. Immunogenicity, safety and efficacy of rhesus-human reassortant rotavirus (RRV-tetravalent) vaccine in Belém, Brazil. Bull World Health Organ 1996; 74: 491-500.
31. Ward RL. Mechanism of protection against rotavirus in humans and mice. J Infect Dis 1996; 174 (suppl 1): 51-58.
32. Burns JW, Siadat-Pajouh M, Krishnaney AA, Greenberg HB. Protective effect of rotavirus VP6-specific IgA monoclonal antibodies that lack neutralizing activity. Science 1996; 272: 104-07.
33. Franco MA, Feng N, Greenberg HB. Molecular determinants of immunity and pathogenicity of rotavirus infection in the mouse model. J Infect Dis 1996; 174 (suppl 1): 47-50.
34. Svensson L, Sheshberadaran H, Wadell G, Norrby E, Vesikari T. Immune response to rotavirus polypeptides after vaccination with heterologous rotavirus vaccines (RIT 4237, RRV-1). J Gen Virol 1987; 68: 1993-99.
35. Offit PA. Host factors associated with protection against rotavirus disease: the skies are clearing. J Infect Dis 1996; 174 (suppl 1): 59-64.
36. O'Ryan ML, Matson DO, Estes MK, Pickering LK. Anti-rotavirus G type-specific and isotype-specific antibodies in children with natural rotavirus infections. J Infect Dis 1994; 169: 504-11.
37. Ward RL, Bernstein EI. Lack of correlation between serum rotavirus antibody titers and protection following vaccination with reassortant RRV vaccines. US Rotavirus Vaccine Efficacy Group. Vaccine 1995; 13: 1226-32.
38. Migasena S, Simasathien S, Samakoses R, et al. Simultaneous administration of oral rhesus-human reassortant tetravalent (RRV-TV) rotavirus vaccine and oral poliovirus vaccine (OPV) in Thai infants. Vaccine 1995; 13: 168-74.
39. Ryan MJ, Ramsay M, Brown D, Gay NJ, Farrington CP, Wall PG. Hospital admissions attributable to rotavirus infection in England and Wales. J Infect Dis 1996; 174 (suppl 1): 12-18.
40. Clark HF, Offit PA, Ellis RW, et al. The development of multivalent bovine rotavirus (strain WC3) reassortant vaccine for infants. J Infect Dis 1996; 174 (suppl 1): 73-80.
41. Conner ME, Zarley CD, Hu B, et al. Virus-like particles as a rotavirus subunit vaccine. J Infect Dis 1996; 174 (suppl 1): 88-92.
42. Herrmann JE, Chen SC, Fynan EF, et al. Protection against rotavirus infections by DNA vaccination. J Infect Dis 1996; 174 (suppl 1): 93-97.